Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNV21-001: Personalized Neo-Antigen Vaccine in Melanoma, Breast Cancer, and NSCLC
NCT05098210Phase 1Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2022
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in melanoma, breast cancer and non-small cell lung cancer (NSCLC), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Incidence of adverse events at 1 year. Started Jun 2022; status: recruiting.
02
Conditions
melanomabreast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05098210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098210.